The use of the exploratory IND in the evaluation and development of 18F-PET radiopharmaceuticals for amyloid imaging in the brain: A review of one company's experience

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 53, Issue 4, 2009, Pages 387-393

  Carpenter Jr , A P ^a   Pontecorvo, M J ^a   Hefti, F F ^a   Skovronsky, D M ^a  

^a AVID RADIOPHARMACEUTICALS   (United States)

Author keywords

Amyloid; Brain; Magnetic resonance imaging; Radiopharmaceuticals

Indexed keywords

AMYLOID; AV 138 F 18; AV 144 F 18; AV 19 F 18; AV 45 F 18; FLUORINE 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; BRAIN CORTEX; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; DRUG ACCUMULATION; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; HUMAN; HUMAN TISSUE; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; QUALITY CONTROL; RADIOCHEMISTRY;

ALZHEIMER DISEASE; AMYLOID; BRAIN; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG INDUSTRY; FLUORINE RADIOISOTOPES; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 74949109430     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (7)

1. Challenges and Opportunities Report - March 2004, "Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products", U.S. Department of Health and Human Services, Food and Drug Administration Internet]. Available from http://www.fda.gov/ScienceResearch/ SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262. htm [cited 2009, Sep 10].
2. Guidance for Industry, Investigators, and Reviewers, Exploratory IND Studies; U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); January 2006. Available from http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm078933.pdf [cited 2009, Sep 10].
3. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F et al. Preclinical Properties of 18F-AV-45: a PET imaging agent for A, plaques in the brain. J Nucl Med 2009 [In press].
4. Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the colinergic hypothesis. Exper Neurol 2000;163:495-529.
5. Watase K, Zoghbi HY. Modeling brain diseases in mice: the challenges of design and analysis. Nat Rev Genetics 2003;4:296-307.
6. Götz J, Streffer JR, David D, Schild A, Hoerndli F, Pennanen L et al. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mole Psych 2004;9:664-83.
7. Hardy J and Selkoe DJ. The amyloid hypothesis of Alzheimer's Disease: progress and problems on the road to therapeutics. Science 2002;297:353-6.